BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
BioCentury | Apr 4, 2011
Strategy

Half-A-Loaf Dilemma

Cephalon Inc. 's board is evaluating the two options in last week's hostile takeover bid from Valeant Pharmaceuticals International Inc. : take the $5.7 billion in cash for the whole company, or take $2.8 billion for...
Items per page:
1 - 2 of 2